Zelira Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZLDAF research report →
About the company
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications.
- CEO
- Oludare Odumosu
- IPO
- 2017
- Employees
- 8
- HQ
- Perth, WA, AU
Price Chart
- Market Cap
- $4.16M
- P/E
- -1.56
- P/S
- 9067.99
- P/B
- -1.29
- EV/EBITDA
- -1.94
- Div Yield
- 0.00%
- Gross Margin
- -122400.15%
- Op Margin
- -602467.84%
- Net Margin
- -553029.27%
- ROE
- 80.84%
- ROIC
- 128.84%
- Revenue
- $656 · -99.31%
- Net Income
- $-3,627,872 · 90.08%
- EPS
- $-0.32 · 90.06%
- Op Income
- $-3,952,189
- FCF YoY
- -11.81%
- 52W High
- $0.42
- 52W Low
- $0.20
- 50D MA
- $0.35
- 200D MA
- $0.31
- Beta
- 0.58
- Avg Volume
- 1
Get TickerSpark's AI analysis on ZLDAF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ZLDAF coverage
Recent articles, reports, and earnings notes.
No research on ZLDAF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZLDAF report →Similar companies
Peers in the same neighborhood.